{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:01:17Z","timestamp":1793836877715,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05318-0","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:37:13Z","timestamp":1761831433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of BRAF-MEK dual inhibition in BRAF-V600E mutated papillary craniopharyngioma: a systematic review"],"prefix":"10.1007","volume":"176","author":[{"given":"Beste","family":"G\u00fclsuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baylee","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belda","family":"G\u00fclsuyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timurhan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika Santos","family":"Horta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Graffeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"5318_CR1","doi-asserted-by":"publisher","first-page":"bnae028","DOI":"10.1210\/endrev\/bnae028","volume":"1","author":"R Prieto","year":"2024","unstructured":"Prieto R, Juratli TA, Bander ED et al (2024) Papillary craniopharyngioma: an integrative and comprehensive review. Endocr Rev Published Online Oct 1:bnae028. https:\/\/doi.org\/10.1210\/endrev\/bnae028","journal-title":"Endocr Rev Published Online Oct"},{"issue":"1","key":"5318_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3171\/jns.1990.73.1.0012","volume":"73","author":"TE Adamson","year":"1990","unstructured":"Adamson TE, Wiestler OD, Kleihues P, Ya\u015fargil MG (1990) Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg 73(1):12\u201317","journal-title":"J Neurosurg"},{"issue":"1","key":"5318_CR3","first-page":"5","volume":"1","author":"E Kahn","year":"1973","unstructured":"Kahn E, Gosch H, Seeger J, Hicks SP (1973) Forty-five years experience with the craniopharyngiomas. Surg Neurol 1(1):5\u201312","journal-title":"Surg Neurol"},{"issue":"4","key":"5318_CR4","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/1097-0142(197604)37:4<1944::AID-CNCR2820370446>3.0.CO;2-#","volume":"37","author":"CK Petito","year":"1976","unstructured":"Petito CK, Degirolami U, Earle KM (1976) Craniopharyngiomas. A clinical and pathological review. Cancer 37(4):1944\u20131952","journal-title":"Cancer"},{"issue":"1","key":"5318_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00000478-198401000-00006","volume":"8","author":"F Giangaspero","year":"1984","unstructured":"Giangaspero F, Burger PC, Osborne DR, Stein RB (1984) Suprasellar papillary squamous epithelioma (papillary craniopharyngioma). Am J Surg Pathol 8(1):57\u201364","journal-title":"Am J Surg Pathol"},{"key":"5318_CR6","unstructured":"Santagata S, Kleinschmidt-DeMasters B, Komori T, M\u00fcller H, Pietsch T Papillary craniopharyngioma. WHO Classif Tumors 5th Ed Cent Nerv Syst Tumours IARC. Published online 2021:397\u2013400"},{"issue":"2","key":"5318_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE et al (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46(2):161\u2013165. https:\/\/doi.org\/10.1038\/ng.2868","journal-title":"Nat Genet"},{"issue":"20","key":"5318_CR8","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/cancers16203479","volume":"16","author":"G Cossu","year":"2024","unstructured":"Cossu G, Ramsay DSC, Daniel RT et al (2024) Update on neoadjuvant and adjuvant BRAF inhibitors in papillary craniopharyngioma: A systematic review. Cancers 16(20):3479. https:\/\/doi.org\/10.3390\/cancers16203479","journal-title":"Cancers"},{"issue":"8","key":"5318_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-Oncol"},{"issue":"6","key":"5318_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1530\/EJE-15-0709","volume":"173","author":"A Hoffmann","year":"2015","unstructured":"Hoffmann A, Boekhoff S, Gebhardt U et al (2015) History before diagnosis in childhood craniopharyngioma: associations with initial presentation and long-term prognosis. Eur J Endocrinol 173(6):853\u2013862. https:\/\/doi.org\/10.1530\/EJE-15-0709","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"5318_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-012-0428-2","volume":"16","author":"EM Erfurth","year":"2013","unstructured":"Erfurth EM, Holmer H, Fjalldal SB (2013) Mortality and morbidity in adult craniopharyngioma. Pituitary 16(1):46\u201355. https:\/\/doi.org\/10.1007\/s11102-012-0428-2","journal-title":"Pituitary"},{"issue":"8","key":"5318_CR12","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00701-021-04832-0","volume":"163","author":"S Ceylan","year":"2021","unstructured":"Ceylan S, Caklili M, Emengen A et al (2021) An endoscopic endonasal approach to craniopharyngioma via the infrachiasmatic corridor: a single center experience of 84 patients. Acta Neurochir (Wien) 163(8):2253\u20132268. https:\/\/doi.org\/10.1007\/s00701-021-04832-0","journal-title":"Acta Neurochir (Wien)"},{"issue":"2","key":"5318_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMe2305288","volume":"389","author":"JO Blakeley","year":"2023","unstructured":"Blakeley JO, Shannon K (2023) Precision oncology for papillary craniopharyngioma. N Engl J Med 389(2):179\u2013181. https:\/\/doi.org\/10.1056\/NEJMe2305288","journal-title":"N Engl J Med"},{"issue":"1","key":"5318_CR14","doi-asserted-by":"publisher","first-page":"e240024","DOI":"10.1530\/EO-24-0024","volume":"4","author":"EM Erfurth","year":"2024","unstructured":"Erfurth EM, Siesj\u00f6 P, Sundgren PC, Hammar B, Kinhult S (2024) Treatment with BRAF\/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma. Endocr Oncol 4(1):e240024. https:\/\/doi.org\/10.1530\/EO-24-0024","journal-title":"Endocr Oncol"},{"issue":"2","key":"5318_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11864-023-01156-2","volume":"25","author":"D Gritsch","year":"2024","unstructured":"Gritsch D, Santagata S, Brastianos PK (2024) Integrating systemic therapies into the multimodality therapy of patients with craniopharyngioma. Curr Treat Options Oncol 25(2):261\u2013273. https:\/\/doi.org\/10.1007\/s11864-023-01156-2","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"5318_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/nop\/npv029","volume":"3","author":"J Varlotto","year":"2016","unstructured":"Varlotto J, DiMaio C, Grassberger C et al (2016) Multi-modality management of craniopharyngioma: a review of various treatments and their outcomes. Neuro-Oncol Pract 3(3):173\u2013187. https:\/\/doi.org\/10.1093\/nop\/npv029","journal-title":"Neuro-Oncol Pract"},{"issue":"5","key":"5318_CR17","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3171\/2023.3.JNS222607","volume":"139","author":"EJ Bobeff","year":"2023","unstructured":"Bobeff EJ, Mathios D, Mistry AA et al (2023) Predictors of extent of resection and recurrence following endoscopic endonasal resection of craniopharyngioma. J Neurosurg 139(5):1235\u20131246. https:\/\/doi.org\/10.3171\/2023.3.JNS222607","journal-title":"J Neurosurg"},{"issue":"20","key":"5318_CR18","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK Inhibition versus BRAF Inhibition alone in melanoma. N Engl J Med 371(20):1877\u20131888. https:\/\/doi.org\/10.1056\/NEJMoa1406037","journal-title":"N Engl J Med"},{"issue":"2","key":"5318_CR19","doi-asserted-by":"publisher","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","volume":"108","author":"PK Brastianos","year":"2016","unstructured":"Brastianos PK, Shankar GM, Gill CM et al (2016) Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst 108(2):djv310. https:\/\/doi.org\/10.1093\/jnci\/djv310","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"5318_CR20","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","volume":"133","author":"A Bernstein","year":"2020","unstructured":"Bernstein A, Mrowczynski OD, Greene A et al (2020) Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. J Neurosurg 133(6):1704\u20131709. https:\/\/doi.org\/10.3171\/2019.8.JNS19643","journal-title":"J Neurosurg"},{"issue":"4","key":"5318_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11102-023-01339-y","volume":"26","author":"AL Lin","year":"2023","unstructured":"Lin AL, Tabar V, Young RJ, Geer EB (2023) Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma. Pituitary 26(4):482\u2013487. https:\/\/doi.org\/10.1007\/s11102-023-01339-y","journal-title":"Pituitary"},{"issue":"15supplement","key":"5318_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1212\/WNL.94.15_supplement.867","volume":"94","author":"M Gopal","year":"2020","unstructured":"Gopal M, Thakur G, Puduvalli V (2020) Initial presentation of papillary craniopharyngioma with BRAF mutation treated with adjuvant chemotherapy (867). Neurology 94(15supplement):867","journal-title":"Neurology"},{"issue":"2","key":"5318_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Twohy E, Geyer S et al (2023) BRAF\u2013MEK Inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med 389(2):118\u2013126. https:\/\/doi.org\/10.1056\/NEJMoa2213329","journal-title":"N Engl J Med"},{"issue":"2","key":"5318_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ejendo\/lvae091","volume":"191","author":"D De Alcubierre","year":"2024","unstructured":"De Alcubierre D, Gkasdaris G, Mordrel M et al (2024) BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study. Eur J Endocrinol 191(2):251\u2013261. https:\/\/doi.org\/10.1093\/ejendo\/lvae091","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"5318_CR25","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","volume":"159","author":"E Rostami","year":"2017","unstructured":"Rostami E, Witt Nystr\u00f6m P, Libard S, Wikstr\u00f6m J, Casar-Borota O, Gudjonsson O (2017) Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir (Wien) 159(11):2217\u20132221. https:\/\/doi.org\/10.1007\/s00701-017-3311-0","journal-title":"Acta Neurochir (Wien)"},{"key":"5318_CR26","doi-asserted-by":"publisher","first-page":"1464362","DOI":"10.3389\/fonc.2024.1464362","volume":"14","author":"P Hanona","year":"2024","unstructured":"Hanona P, Ezekwudo D, Anderson J (2024) Clinical response to Dabrafenib plus Trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review. Front Oncol 14:1464362. https:\/\/doi.org\/10.3389\/fonc.2024.1464362","journal-title":"Front Oncol"},{"key":"5318_CR27","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.wneu.2023.08.137","volume":"180","author":"ZP Wu","year":"2023","unstructured":"Wu ZP, Wang YL, Wang LC et al (2023) Case report: successful use of BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. World Neurosurg 180:e117\u2013e126. https:\/\/doi.org\/10.1016\/j.wneu.2023.08.137","journal-title":"World Neurosurg"},{"issue":"9","key":"5318_CR28","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.21873\/anticanres.15919","volume":"42","author":"P Palmisciano","year":"2022","unstructured":"Palmisciano P, Young K, Ogasawara M et al (2022) Craniopharyngiomas invading the ventricular system: A systematic review. Anticancer Res 42(9):4189\u20134197. https:\/\/doi.org\/10.21873\/anticanres.15919","journal-title":"Anticancer Res"},{"issue":"5","key":"5318_CR29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00701-020-04265-1","volume":"162","author":"G Cossu","year":"2020","unstructured":"Cossu G, Jouanneau E, Cavallo LM et al (2020) Surgical management of craniopharyngiomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section. Acta Neurochir (Wien) 162(5):1159\u20131177. https:\/\/doi.org\/10.1007\/s00701-020-04265-1","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"5318_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10143-025-03238-1","volume":"48","author":"HJ Yoo","year":"2025","unstructured":"Yoo HJ, Ham CH, Roh H et al (2025) Radiosurgery versus radiation therapy for long term local control rate of craniopharyngioma: a meta-analysis. Neurosurg Rev 48(1):93. https:\/\/doi.org\/10.1007\/s10143-025-03238-1","journal-title":"Neurosurg Rev"},{"issue":"1","key":"5318_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00701-024-05980-9","volume":"166","author":"G Kohli","year":"2024","unstructured":"Kohli G, Gabriel PJ, Brady M, Fang CH, Eloy JA, Liu JK (2024) The role of endoscopic endonasal salvage surgery in recurrent or residual craniopharyngioma after a transcranial approach: a systematic review. Acta Neurochir (Wien) 166(1):120. https:\/\/doi.org\/10.1007\/s00701-024-05980-9","journal-title":"Acta Neurochir (Wien)"},{"key":"5318_CR32","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1016\/j.wneu.2023.04.037","volume":"175","author":"KL Webb","year":"2023","unstructured":"Webb KL, Pruter WW, Hinkle ML, Walsh MT (2023) Comparing surgical approaches for craniopharyngioma resection among adults and children: A Meta-analysis and systematic review. World Neurosurg 175:e876\u2013e896. https:\/\/doi.org\/10.1016\/j.wneu.2023.04.037","journal-title":"World Neurosurg"},{"issue":"5","key":"5318_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1470-2045(23)00146-8","volume":"24","author":"TE Merchant","year":"2023","unstructured":"Merchant TE, Hoehn ME, Khan RB et al (2023) Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study. Lancet Oncol 24(5):523\u2013534. https:\/\/doi.org\/10.1016\/S1470-2045(23)00146-8","journal-title":"Lancet Oncol"},{"key":"5318_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.wneu.2022.05.038","volume":"164","author":"M Castle-Kirszbaum","year":"2022","unstructured":"Castle-Kirszbaum M, Shi MDY, Goldschlager T (2022) Quality of life in craniopharyngioma: A systematic review. World Neurosurg 164:424\u2013435e2. https:\/\/doi.org\/10.1016\/j.wneu.2022.05.038","journal-title":"World Neurosurg"},{"key":"5318_CR35","doi-asserted-by":"publisher","first-page":"652005","DOI":"10.3389\/fmed.2021.652005","volume":"8","author":"M Fasano","year":"2022","unstructured":"Fasano M, Della Corte CM, Caterino M et al (2022) Dramatic therapeutic response to Dabrafenib plus Trametinib in BRAF V600E mutated papillary craniopharyngiomas: A case report and literature review. Front Med 8:652005. https:\/\/doi.org\/10.3389\/fmed.2021.652005","journal-title":"Front Med"},{"issue":"12","key":"5318_CR36","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","volume":"18","author":"K Khaddour","year":"2020","unstructured":"Khaddour K, Chicoine MR, Huang J, Dahiya S, Ansstas G (2020) Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma. J Natl Compr Canc Netw 18(12):1590\u20131595. https:\/\/doi.org\/10.6004\/jnccn.2020.7624","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"5318_CR37","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.32197","volume":"125","author":"TA Juratli","year":"2019","unstructured":"Juratli TA, Jones PS, Wang N et al (2019) Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 125(17):2910\u20132914. https:\/\/doi.org\/10.1002\/cncr.32197","journal-title":"Cancer"},{"issue":"2","key":"5318_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/cns-2016-0034","volume":"6","author":"A Roque","year":"2017","unstructured":"Roque A, Odia Y (2017) BRAF -V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol 6(2):95\u201399. https:\/\/doi.org\/10.2217\/cns-2016-0034","journal-title":"CNS Oncol"},{"issue":"1","key":"5318_CR39","doi-asserted-by":"publisher","first-page":"vdaa141","DOI":"10.1093\/noajnl\/vdaa141","volume":"2","author":"AL Di Stefano","year":"2020","unstructured":"Di Stefano AL, Guyon D, Sejean K et al (2020) Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF -mutant craniopharyngioma. Neuro-Oncol Adv 2(1):vdaa141. https:\/\/doi.org\/10.1093\/noajnl\/vdaa141","journal-title":"Neuro-Oncol Adv"},{"key":"5318_CR40","doi-asserted-by":"publisher","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","volume":"13","author":"F Calvanese","year":"2022","unstructured":"Calvanese F, Jacquesson T, Manet R et al (2022) Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: A new treatment paradigm. Front Endocrinol 13:882381. https:\/\/doi.org\/10.3389\/fendo.2022.882381","journal-title":"Front Endocrinol"},{"key":"5318_CR41","doi-asserted-by":"publisher","unstructured":"Shah SN, Kaki PC, Shah SS, Shah SA (2023) Concurrent radiation and targeted therapy for papillary craniopharyngioma: A case report. Cureus Published Online June 9. https:\/\/doi.org\/10.7759\/cureus.40190","DOI":"10.7759\/cureus.40190"},{"issue":"11","key":"5318_CR42","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s40618-024-02382-7","volume":"47","author":"M Losa","year":"2024","unstructured":"Losa M, Mazza E, Pedone E et al (2024) Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature. J Endocrinol Invest 47(11):2835\u20132842. https:\/\/doi.org\/10.1007\/s40618-024-02382-7","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"5318_CR43","doi-asserted-by":"publisher","first-page":"CNS106","DOI":"10.2217\/cns-2023-0018","volume":"13","author":"N Yu","year":"2024","unstructured":"Yu N, Raslan OA, Lee HS et al (2024) Promising response to Vemurafenib and Cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review. CNS Oncol 13(1):CNS106. https:\/\/doi.org\/10.2217\/cns-2023-0018","journal-title":"CNS Oncol"},{"issue":"1","key":"5318_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11060-025-04969-3","volume":"173","author":"M Damante","year":"2025","unstructured":"Damante M, Cua S, Kreatsoulas D et al (2025) Papillary craniopharyngioma management in the era of BRAF and MEK Inhibition. J Neurooncol 173(1):225\u2013232. https:\/\/doi.org\/10.1007\/s11060-025-04969-3","journal-title":"J Neurooncol"},{"issue":"1","key":"5318_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","volume":"4","author":"A H\u00f6lsken","year":"2016","unstructured":"H\u00f6lsken A, Sill M, Merkle J et al (2016) Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 4(1):20. https:\/\/doi.org\/10.1186\/s40478-016-0287-6","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"5318_CR46","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/cas.16097","volume":"115","author":"Y Bao","year":"2024","unstructured":"Bao Y, Zhang D, Guo H, Ma W (2024) Beyond blood: advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Sci 115(4):1060\u20131072. https:\/\/doi.org\/10.1111\/cas.16097","journal-title":"Cancer Sci"},{"issue":"12","key":"5318_CR47","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/neuonc\/noz156","volume":"21","author":"AK Mattox","year":"2019","unstructured":"Mattox AK, Yan H, Bettegowda C (2019) The potential of cerebrospinal fluid\u2013based liquid biopsy approaches in CNS tumors. Neuro-Oncol 21(12):1509\u20131518. https:\/\/doi.org\/10.1093\/neuonc\/noz156","journal-title":"Neuro-Oncol"},{"issue":"9","key":"5318_CR48","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3390\/cancers13091989","volume":"13","author":"L Escudero","year":"2021","unstructured":"Escudero L, Mart\u00ednez-Ricarte F, Seoane J (2021) ctDNA-Based liquid biopsy of cerebrospinal fluid in brain cancer. Cancers 13(9):1989. https:\/\/doi.org\/10.3390\/cancers13091989","journal-title":"Cancers"},{"issue":"1","key":"5318_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13148-025-01836-w","volume":"17","author":"X Deng","year":"2025","unstructured":"Deng X, Li P, Tian K et al (2025) Radiogenomic method combining DNA methylation profiles and magnetic resonance imaging radiomics predicts patient prognosis in skull base Chordoma. Clin Epigenetics 17(1):23. https:\/\/doi.org\/10.1186\/s13148-025-01836-w","journal-title":"Clin Epigenetics"},{"key":"5318_CR50","unstructured":"Phase II, Trial of BRAF\/MEK Inhibitors in Papillary Craniopharyngiomas (2017). Published online July 19, Accessed January 6, 2018. https:\/\/clinicaltrials.gov\/study\/NCT03224767"},{"key":"5318_CR51","unstructured":"Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma. Published online April 20 (2022) Accessed September 2, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05525273"},{"key":"5318_CR52","unstructured":"Nivolumab and Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults. Published online July 15 (2022) Accessed September 13, 2022. https:\/\/clinicaltrials.gov\/study\/NCT05465174"}],"updated-by":[{"DOI":"10.1007\/s11060-025-05341-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000}}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05318-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:53Z","timestamp":1767702893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05318-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5318"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05318-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11060-025-05341-1","URL":"https:\/\/doi.org\/10.1007\/s11060-025-05341-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}